Declining funding undermines Africa’s vision to eliminate malaria - The EastAfrican

Africa's ambitious malaria elimination agenda faces a critical juncture as international funding mechanisms show signs of fatigue. This development carries significant implications not only for public health outcomes across the continent but also for European investors whose market entry strategies depend on stable healthcare infrastructure and workforce productivity. The funding shortfall represents a concerning reversal of progress made over the past two decades. Between 2000 and 2015, aggressive investment in malaria control programs—primarily from bilateral donors, multilateral institutions, and philanthropic organizations—helped reduce malaria mortality rates by approximately 60% across sub-Saharan Africa. However, recent data indicates that funding growth has stalled and, in some regions, contracted in real terms. The Global Fund to Fight AIDS, Tuberculosis and Malaria, historically the largest multilateral contributor, has faced increasing pressure to allocate resources across competing health priorities, effectively reducing the malaria-specific budget envelope. This financing crisis occurs at a particularly inopportune moment. While progress against malaria has been substantial, approximately 95% of global malaria deaths still occur in Africa, with the disease remaining a leading cause of morbidity and mortality in working-age populations. The World Health Organization estimates that malaria costs African economies between 1-3% of GDP annually through direct healthcare expenditures and indirect